joaquin martinez lopez
joaquin martinez lopez
Hospital universitario 12 de Octubre, CNIO, Universidad Complutense
Dirección de correo verificada de ucm.es
TítuloCitado porAño
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label …
J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ...
The lancet oncology 14 (11), 1055-1066, 2013
6472013
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...
New England Journal of Medicine 375 (8), 754-766, 2016
6322016
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide …
MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ...
The lancet oncology 11 (10), 934-941, 2010
4862010
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
4572016
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ...
Blood 120 (8), 1589-1596, 2012
3902012
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
BA Thompson, AB Spurdle, JP Plazzer, MS Greenblatt, K Akagi, ...
Nature genetics 46 (2), 107, 2014
3012014
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
J Martinez-Lopez, JJ Lahuerta, F Pepin, M González, S Barrio, R Ayala, ...
Blood 123 (20), 3073-3079, 2014
2882014
Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are …
JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ...
Journal of Clinical Oncology 26 (35), 5775-5782, 2008
2772008
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ...
New England Journal of Medicine 378 (6), 518-528, 2018
2402018
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
N Engl J Med 78 (6), 518-528, 2018
240*2018
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation …
B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ...
Blood 119 (3), 687-691, 2012
2292012
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ...
J Clin Oncol 29 (12), 1627-1633, 2011
2142011
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry
ME Sarasquete, R García-Sanz, D González, J Martínez, G Mateo, ...
haematologica 90 (10), 1365-1372, 2005
1962005
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
J Martinez-Lopez, J Blade, MV Mateos, C Grande, A Alegre, ...
Blood 118 (3), 529-534, 2011
1762011
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ...
Leukemia 31 (10), 2094, 2017
1662017
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, ...
Blood 120 (13), 2581-2588, 2012
1512012
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N Puig, ME Sarasquete, A Balanzategui, J Martinez, B Paiva, H Garcia, ...
Leukemia 28 (2), 391, 2014
1422014
Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
JJ Lahuerta, J Martinez‐Lopez, J Serna, J Bladé, C Grande, A Alegre, ...
British Journal of Haematology: TRANSPLANTATION 109 (2), 438-446, 2000
1292000
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
R Villuendas, JL Steegmann, M Pollan, L Tracey, A Granda, ...
Leukemia 20 (6), 1047, 2006
1152006
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ...
The Lancet Oncology 19 (6), 747-757, 2018
1012018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20